Investigating [68Ga]Ga-FAPI-04 PET/CT for High-Grade Neuroendocrine Cancer
This study is testing an investigational scan called [68Ga]Ga-FAPI-04 PET/CT for people with high-grade neuroendocrine cancer. Researchers want to see where the imaging agent, Gallium Ga 68-DOTA-FAPI-04, goes in the body and how it moves through the system. This helps them understand if it can effectively highlight cancer cells. You might be able to join if you are 18 or older, have a high-grade neuroendocrine tumor, and can lie flat for 60 minutes. The study aims to enroll 30 participants. The current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 30 participants. It is an early phase trial, meaning it's focused on understanding how the investigational scan works in the body.
- What's involved
- You would undergo a CT scan and a PET scan, which involves receiving Gallium Ga 68-DOTA-FAPI-04 intravenously (IV).
- Compensation
- Not stated in the trial record.
- Follow-up
- Your biodistribution and pharmacokinetics (how the drug moves through your body) will be measured on Day 1.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Benjamin Viglianti · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Biodistribution of Gallium Ga 68-DOTA-FAPI-04 ([68Ga]Ga-FAPI-04)Day 1
- Pharmacokinetics of [68Ga] Ga-FAPI-04Day 1
We will monitor/measure the amount of Ga-FAPI-04 seen within different tissue in patients that have neuroendocrine tumors. We will specifically measure the ratio of uptake in the tumors in comparison to reference tissues such as liver or muscle.